In November 2008, the Global Fund to Fight HIV/AIDS, TB and Malaria announced that it would administer the first phase of an ambitious scheme to increase the availability of effective treatment for malaria, the Affordable Medicines Facility – malaria (AMFm). Artemisinin‐based combination
therapies (ACTs) are highly‐effective, but remain prohibitively expensive for those who are most vulnerable to malaria infection. AMFm aims to reduce significantly the price of ACTs by offering a co‐payment for ACTs purchased by eligible buyers at the top of the supply chain.
Recognizing that the public and private sectors are important sources of antimalarials in most endemic countries, both public and private sector buyers will be entitled to purchase subsidized ACTs. The involvement of the private sector is an innovative element of AMFm, as many countries
already have experience distributing ACTs in the public sector. To ensure that subsidized ACTs reach patients at the lowest possible cost, it is necessary to gain a better understanding of the private sector supply chains for antimalarials in each country participating in AMFm.
The objective of the rapid supply chain survey was therefore to assist Benin, which is one of the 11 countries invited to apply to the first phase of AMFm, in the development of an effective implementation plan by providing an understanding of the current supply chain for antimalarials,
and the way in which subsidised ACTs are likely to travel through this chain to reach patients. This report presents the findings of a series of semi‐structured interviews conducted with government
officials and private suppliers of malaria treatment operating at the various levels of the chain...